On January 5, InSilicon announced a collaboration with Servier for the research and development of anti-cancer drugs, with a total value of $888 million. Under the agreement, Insilico will be eligible to receive an upfront payment of up to $32 million, as well as near-term R&D milestone payments, and will lead the discovery and development of potential drug candidates that meet established criteria using its AI technology platform; Servier will share R&D costs and lead subsequent clinical validation and commercialization efforts.